Auayporn Nademanee is an Oncology physician affiliated with City Of Hope National Medical Center. OpenAlex indexes 293 publications with 12,488 citations (h-index 56); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3229 Steven Dr
Encino, CA 914364225
Telephone
818-888-8888Provider last certified this registry record 7 Feb 2020.
Clinical trials
- Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
Sponsor: City of Hope Medical Center
- Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Sponsor: City of Hope Medical Center
- Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
Sponsor: City of Hope Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
35.3%Statin35.3%Atorvastatin Calcium100%Part D<11 patientsDermatology
32.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor32.4%Acyclovir100%Part D<11 patientsAnti-infectives
32.4%Short-acting sulfonamides32.4%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2004–2004 per NIH RePORTER. The latest:
- A Phase I/II Trial of Escalating Dose of Yttrium-90
University of Southern California
FY2004$21,397M01RR000043
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients
Annals of Internal Medicine
2020 - NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
Journal of the National Comprehensive Cancer Network
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Yuman Fong, MD
City Of Hope National Medical Center
Ravi Salgia, MD, PhD
City Of Hope National Medical Center
Stephen Gruber, MD
City Of Hope National Medical Center
Tanya Siddiqi, MD
City Of Hope National Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”